WOONSOCKET, R.I. – Omnicare, a subsidiary of CVS Health, announced Wednesday that it has entered into an asset purchase agreement with GenieRx Holdings, a joint partnership between private investment firm Milrose Capital and health-care investment and management firm Integro Asset Management, which does business as Integro Healthcare Services. GenieRx will serve as the "stalking horse bidder" in the company's ongoing court‑supervised sale process.
"We are making meaningful progress in our court‑supervised process and are pleased to enter into this purchase agreement with GenieRx," said David Azzolina, president of Omnicare. "GenieRx's interest reflects the strength of Omnicare's clinical expertise, the trust we have earned from the skilled nursing and senior living communities we serve, and the essential role our teams play in supporting high‑quality care for residents. We are grateful for the continued support of our customers and for the dedication of our colleagues, who remain focused every day on serving residents with care and professionalism."
Omnicare continues to focus on helping skilled nursing and assisted living providers navigate the increasing clinical, regulatory, and operational complexity of long‑term care. As the sale process moves forward, the Company remains engaged with skilled nursing facilities through transparent pricing approaches, clinical programs aligned with CMS value‑based purchasing measures, and analytics that support ISNPs, ACOs, and other risk‑bearing care models.
For assisted living communities, Omnicare continues to emphasize a partnership‑driven approach to pharmacy services, programs designed to support rising resident acuity and aging‑in‑place, and ongoing improvements to billing, delivery, and communication experiences for operators and residents.
Throughout the court‑supervised process, Omnicare remains focused on supporting its customers and ensuring residents continue to receive safe, reliable pharmacy care.
Additional Information About the Court-Supervised Sale Process
As part of Omnicare's ongoing court-supervised process, GenieRx will serve as a "stalking horse bidder", whereby the agreement with GenieRx will set the floor for the sale of the Company's assets. Accordingly, the proposed agreement is subject to higher or otherwise better offers from other qualified bidders.
The deadline for interested parties to submit competing bids is April 30, 2026. If qualified bids are received, an auction is expected to be held on May 5, 2026. A hearing to approve the sale to the winning bidder will be scheduled shortly thereafter, subject to the availability of the Court.
Additional information regarding Omnicare's court-supervised process is available at www.OmnicareRestructuring.com.
